← Leaderboards
Ronald C Montelaro
University Of Pittsburgh At Pittsburgh
$16,007,779
Attributed
$16,007,779
Total exposure
19
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2005–14$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$16,007,779 · 19
By mechanism
R01$12,454,634 · 4
T32$1,277,809 · 1
P30$1,076,384 · 3
R21$424,489 · 1
P01$351,855 · 1
R56$293,945 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Michael S. Diamond$85,358,908
- Jonathan Pieter Vande Geest$8,379,230
- Cristian Apetrei$24,938,676
- Robert P Bowser$16,513,448
- Roger W Hendrix$9,668,287
Others in their field
Top investigators on “Hiv-1”
- Barton F Haynes · Duke University$476,288,740
- Lawrence Corey · Fred Hutchinson Cancer Center$445,419,385
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$294,186,693
- Constance Ann Benson · University Of California, San Diego$272,046,180
- Peter B. Gilbert · Fred Hutchinson Cancer Center$173,010,936
- Dan H. Barouch · Fred Hutchinson Cancer Center$166,542,502
Research focus
Hiv-1InfectionVariantAids VaccinesViralEquine Infectious Anemia VirusAntibody FormationVaccine DevelopmentVirusVirus AntigenPropertySpecificityInsightBaseVaccinesImmunogenicityAffectGrantAttenuatedSeriesPathogenesisAntigensDesignImmunization
Grant awards (58)
Topology, Antigenicity, and Immunogenicity of the C-terminal Tail (CTT) of HIV-1$515,072
R01 · FY2014 · AI · contact PI
EIAV Envelope Variation and Vaccine Efficacy$632,994
R01 · FY2013 · AI · contact PI
Topology, Antigenicity, and Immunogenicity of the C-terminal Tail (CTT) of HIV-1$487,379
R01 · FY2013 · AI · contact PI
EIAV Envelope Variation and Vaccine Efficacy$681,025
R01 · FY2012 · AI · contact PI
Topology, Antigenicity, and Immunogenicity of the C-terminal Tail (CTT) of HIV-1$526,740
R01 · FY2012 · AI · contact PI
EIAV Envelope Variation and Vaccine Efficacy$689,250
R01 · FY2011 · AI · contact PI
Topology, Antigenicity, and Immunogenicity of the C-terminal Tail (CTT) of HIV-1$542,075
R01 · FY2011 · AI · contact PI
EIAV Envelope Variation and Vaccine Efficacy$697,023
R01 · FY2010 · AI · contact PI
Topology, Antigenicity, and Immunogenicity of the C-terminal Tail (CTT) of HIV-1$569,670
R01 · FY2010 · AI · contact PI
ANIMAL MODELS FOR AIDS VACCINE DEVELOPMENT$1,091
P41 · FY2010 · RR · contact PI
EIAV Envelope Variation and Vaccine Efficacy$719,298
R01 · FY2009 · AI · contact PI
ANIMAL MODELS FOR AIDS VACCINE DEVELOPMENT$771
P41 · FY2009 · RR · contact PI
ANIMAL MODELS FOR AIDS VACCINE DEVELOPMENT$473
P41 · FY2008 · RR · contact PI
Equine Infectious Anemia Virus Envelope Variation and Vaccine Efficacy$595,906
R01 · FY2007 · AI · contact PI
Cellular and Molecular Biology of EIAV Replication$293,945
R56 · FY2007 · AI · contact PI
Evaluation of HIV-1 Env intracytoplasmic domain as an AIDS vaccine immunogen$209,014
R21 · FY2007 · AI · contact PI
ANIMAL MODELS FOR AIDS VACCINE DEVELOPMENT$673
P41 · FY2007 · RR · contact PI
EIAV Envelope Variation and Vaccine Efficacy$618,242
R01 · FY2006 · AI · contact PI
Evaluation of HIV-1 Env intracytoplasmic domain as an AIDS vaccine immunogen$215,475
R21 · FY2006 · AI · contact PI
ANIMAL MODELS FOR AIDS VACCINE DEVELOPMENT$2,203
P41 · FY2006 · RR · contact PI
EIAV Envelope Variation and Vaccine Efficacy$608,093
R01 · FY2005 · AI
Cellular and Molecular Biology of EIAV Replication$294,678
R01 · FY2005 · CA
Molecular Microbial Persistence and Pathogenesis$281,197
T32 · FY2005 · AI
ANIMAL MODELS FOR AIDS VACCINE DEVELOPMENT$3,833
P41 · FY2005 · RR
EIAV Envelope Variation and Vaccine Efficacy$616,652
R01 · FY2004 · AI
Cellular and Molecular Biology of EIAV Replication$294,437
R01 · FY2004 · CA
Molecular Microbial Persistence and Pathogenesis$285,546
T32 · FY2004 · AI
DOMAIN-SPECIFIC SEROLOGY FOR SIV/SHIV VACCINE EVALUATION$266,135
R01 · FY2004 · AI
PEPTIDE FACILITY$74,768
P30 · FY2004 · CA
ANIMAL MODELS FOR AIDS VACCINE DEVELOPMENT$5,450
P41 · FY2004 · RR
EIAV Envelope Variation and Vaccine Efficacy$309,211
R01 · FY2003 · AI
Cellular and Molecular Biology of EIAV Replication$293,781
R01 · FY2003 · CA
Molecular Microbial Persistence and Pathogenesis$279,338
T32 · FY2003 · AI
DOMAIN-SPECIFIC SEROLOGY FOR SIV/SHIV VACCINE EVALUATION$266,817
R01 · FY2003 · AI
Cellular and Molecular Biology of EIAV Replication$292,762
R01 · FY2002 · CA
Molecular Microbial Persistence and Pathogenesis$265,276
T32 · FY2002 · AI
Core--DNA sequencing$250,404
P30 · FY2002 · CA
Molecular virology program$250,404
P30 · FY2002 · CA
DOMAIN-SPECIFIC SEROLOGY FOR SIV/SHIV VACCINE EVALUATION$240,697
R01 · FY2002 · AI
ANIMAL MODELS FOR AIDS VACCINE DEVELOPMENT$0
P41 · FY2002 · RR
ANIMAL MODELS FOR AIDS VACCINE DEVELOPMENT$0
P41 · FY2002 · RR
ANALYSES OF HUMORAL IMMUNE RESPONSES TO SIV/SHIV VACCINES$0
P01 · FY2002 · AI
IMMUNOLOGIC MANAGEMENT OF LENTIVIRUS INFECTIONS--EIAV$449,659
R01 · FY2001 · AI
DOMAIN-SPECIFIC SEROLOGY FOR SIV/SHIV VACCINE EVALUATION$268,009
R01 · FY2001 · AI
Molecular virology program$250,404
P30 · FY2001 · CA
Core--DNA sequencing$250,404
P30 · FY2001 · CA
Molecular Microbial Persistence and Pathogenesis$166,452
T32 · FY2001 · AI
ANALYSES OF HUMORAL IMMUNE RESPONSES TO SIV/SHIV VACCINES$0
P01 · FY2001 · AI
ANIMAL MODELS FOR AIDS VACCINE DEVELOPMENT$0
P41 · FY2001 · RR
Core--DNA sequencing$0
P30 · FY2001 · CA
Molecular virology program$0
P30 · FY2001 · CA
IMMUNOLOGIC MANAGEMENT OF LENTIVIRUS INFECTIONS--EIAV$438,007
R01 · FY2000 · AI
ANALYSES OF HUMORAL IMMUNE RESPONSES TO SIV/SHIV VACCINES$351,855
P01 · FY2000 · AI
DOMAIN-SPECIFIC SEROLOGY FOR SIV/SHIV VACCINE EVALUATION$280,623
R01 · FY2000 · AI
REGULATION OF EIAV REPLICATION AND DISEASE$260,399
R01 · FY2000 · CA
CORE--MOLECULAR BIOLOGY$114,169
P60 · FY2000 · AR
Core--DNA sequencing$0
P30 · FY2000 · CA
Molecular virology program$0
P30 · FY2000 · CA